View : 679 Download: 0
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
- Title
- Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
- Authors
- Ahn, Jae-Sook; Kim, Yeo-Kyeoung; Min, Yoo Hong; Cheong, June-Won; Jang, Jun Ho; Jung, Chul Won; Kim, In Ho; Yoon, Hwi-Joong; Lee, Hong Ghi; Sohn, Sang Kyun; Moon, Joon Ho; Kim, Hawk; Kim, Yoo-Jin; Won, Jong-Ho; Chung, Joo-Seop; Mun, Yeung Chul; Lee, Je-Hwan; Kim, Hyeoung-Joon|Korean Soc Hematology AML MDS Work
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2015
- Journal Title
- ACTA HAEMATOLOGICA
- ISSN
- 0001-5792
1421-9662
- Citation
- ACTA HAEMATOLOGICA vol. 134, no. 1, pp. 40 - 48
- Keywords
- Myelodysplastic syndrome; Azacitidine; Allogeneic stem cell transplantation
- Publisher
- KARGER
- Indexed
- SCI; SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Azacitidine (AZA) is commonly used in patients with myelo-dysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twentyone patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS. (C) 2015 S. Karger AG, Basel
- DOI
- 10.1159/000368711
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML